01—Abstract
Summary
Summary of the 8-K filed February 11, 2026. Cited figures are marked; the original filing is the authoritative source.
Neurocrine Biosciences, Inc. reported fourth-quarter and full-year 2025 results on February 11, 2026, as detailed in Exhibit 99.1.
Total net product sales were $798.3 milliona for the fourth quarter and $2.83 billion for the full year, reflecting year-over-year growth of 29% and 22%, respectively. INGREZZA net product sales were $657.5 million in the fourth quarter and $2.51 billion for the full year, up 7% and 9% year-over-year. CRENESSITY net product sales were $135.3 million in the fourth quarter and $301.2 million for the full year, with 431 and 2,048 total new patient enrollment start forms, respectively.
Fourth-quarter GAAP net income was $153.7 millionb ($1.48 per diluted share), compared with $103.1 million ($1.00) a year earlier. Full-year GAAP net income was $478.6 million ($4.67 per diluted share). Non-GAAP diluted EPS was $1.88 for the fourth quarter and $6.39 for the full year.
Cash, cash equivalents, and marketable securities totaled approximately $2.54 billionc at December 31, 2025. For 2026, the company guided to INGREZZA net product sales of $2.7 to $2.8 billion, GAAP R&D expense of $1.200 to $1.250 billion, and GAAP SG&A expense of $1.375 to $1.400 billion. Management highlighted advancing Phase 3 programs for osavampator in major depressive disorder and direclidine in schizophrenia, along with the initiation of a Phase 2 study of NBI-1065890 in adults with tardive dyskinesia.
Operating expense increases in 2025 reflected expanded R&D investment, incremental CRENESSITY launch spending, and upfront payments for early-stage development candidate licenses. The filing notes that the information furnished under Item 2.02 is not deemed "filed" for purposes of Section 18 of the Exchange Act. Investors should review the GAAP-to-non-GAAP reconciliations in the attached tables, since the company excludes items such as stock-based compensation, which totaled $126.9 milliond in SG&A and $91.0 million in R&D for the full year.
02—Key points
Key Highlights
- Full-year 2025 total net product sales of $2.83 billion grew 22% year-over-year; fourth-quarter net product sales of $798.3 million grew 29%.
- INGREZZA full-year 2025 net product sales were $2.51 billion (up 9%), with double-digit prescription volume growth in TRx and NRx partially offset by lower net price from formulary access investments.
- CRENESSITY generated $301.2 million in full-year 2025 net product sales and $135.3 million in the fourth quarter, with 2,048 total new patient enrollment start forms for the year.
- Full-year 2025 GAAP net income was $478.6 million ($4.67 diluted EPS) versus $341.3 million ($3.29) in 2024; non-GAAP diluted EPS was $6.39 versus $6.33.
- 2026 guidance calls for INGREZZA net product sales of $2.7 to $2.8 billion, GAAP R&D expense of $1.200 to $1.250 billion, and GAAP SG&A expense of $1.375 to $1.400 billion.
- Cash, cash equivalents, and marketable securities totaled approximately $2.54 billion at December 31, 2025, up from $1.82 billion a year earlier.
- Pipeline progress includes Phase 3 programs for osavampator (major depressive disorder) and direclidine (schizophrenia), and a new Phase 2 study of NBI-1065890 in tardive dyskinesia.
03—Questions
Frequently Asked Questions
How did Neurocrine's sales perform in 2025?
Total net product sales were $2.83 billion for the full year 2025, up 22% year-over-year, and $798.3 million for the fourth quarter, up 29%. INGREZZA contributed $2.51 billion for the year (up 9%) and CRENESSITY contributed $301.2 million.
What is the company's 2026 financial guidance?
The company expects INGREZZA net product sales of $2.7 to $2.8 billion in 2026. GAAP R&D expense is guided to $1.200 to $1.250 billion, GAAP SG&A expense to $1.375 to $1.400 billion, and GAAP and non-GAAP IPR&D to $20 million each. Non-GAAP R&D is guided to $1.110 to $1.160 billion and non-GAAP SG&A to $1.240 to $1.265 billion.
Why did operating expenses rise in 2025?
The filing attributes higher expenses to increased R&D supporting the expanded pipeline, including the osavampator Phase 3 program in major depressive disorder and the direclidine Phase 3 program in schizophrenia; increased SG&A for CRENESSITY launch activities and continued INGREZZA investment; and higher acquired IPR&D from upfront payments for early-stage development candidate licenses.
What was the difference between GAAP and non-GAAP earnings?
Full-year 2025 GAAP net income was $478.6 million ($4.67 per diluted share), while non-GAAP net income was $654.5 million ($6.39 per diluted share). The largest adjustments were stock-based compensation of $126.9 million in SG&A and $91.0 million in R&D, partly offset by an income tax effect of $(55.1) million.
What is the company's cash position and what are the next pipeline milestones?
Cash, cash equivalents, and marketable securities totaled approximately $2.54 billion at December 31, 2025, compared with $1.82 billion a year earlier. The company cited ongoing Phase 3 programs for osavampator in major depressive disorder and direclidine in schizophrenia, and a Phase 2 study of NBI-1065890 in adults with tardive dyskinesia that it initiated during the period.
04—Continue